Newsfeeds - Spark Newswire

1 minute read

Chimerix’s CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies

Today, 11:23 AM

Chimerix Inc's (NASDAQ: CMRX) preclinical data from its CMX521 program will be featured at the International Conference on Antiviral Research (ICAR) in March.

CMRX

2 minute read

Chimerix Announces Publication Of ONC201 Data From Phase 2 Study In Neuroendocrine Tumors In Clinical Cancer Research

By Benzinga Newsdesk

Today, 11:23 AM

Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that a peer-reviewed

CMRX

1 minute read

Chimerix Sam.gov Site Contract Listing For Co.’s Smallpox Antiviral,’ Size Of Contract Not Disclosed

By Benzinga Newsdesk

Today, 11:23 AM

https://sam.gov/opp/e49ceeaa454f402e966062743f84ead1/view

CMRX

1 minute read

10 Biggest Price Target Changes For Wednesday

By Lisa Levin

Today, 11:23 AM

Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.

ADGI

1 minute read

HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $24

By Benzinga Newsdesk

Today, 11:23 AM

HC Wainwright & Co. analyst Edward White maintains Chimerix (NASDAQ:CMRX) with a Buy and raises the price target from $21 to $24.

CMRX

4 minute read

52 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:23 AM

ACET

1 minute read

‘$CMRX BARDA has posted a notice of intent to negotiate a sole source contract with Chimerix Inc for the development and procurement of a smallpox therapeutic with a mechanism of action distinct from that of TPOXX ($SIGA)’ -TradeHawk Tweet

By Bill Haddad

Today, 11:23 AM

https://twitter.com/TradeHawk/status/1465417582819758084?s=20

CMRX

1 minute read

HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $21

By Benzinga Newsdesk

Today, 11:23 AM

HC Wainwright & Co. analyst Edward White maintains Chimerix (NASDAQ:CMRX) with a Buy and raises the price target from $19 to $21.

CMRX

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline

Today, 11:23 AM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 11:23 AM

ARTL